Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siWee1 is a small interfering RNA (siRNA) designed to silence the expression of the Wee1 kinase, a key regulator of the G2/M cell cycle checkpoint. By inhibiting Wee1, siWee1 prevents the inhibitory phosphorylation of CDK1 (Tyr15), leading to premature entry into mitosis or cell cycle arrest in G1/S and S phases, particularly in cancer cells with dysfunctional G1 checkpoints. In preclinical studies of malignant melanoma, siWee1 treatment has been shown to induce DNA damage (marked by γ-H2AX), reduce cell viability, and trigger apoptosis through caspase-3 and PARP cleavage. It is primarily used as a research tool to validate Wee1 as a therapeutic target in various malignancies, including melanoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siWee1.